U.S., Nov. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07226778) titled 'Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations' on Nov. 07.
Brief Summary: The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.
Study Start Date: Oct. 10
Study Type: INTERVENTIONAL
Condition:
Overweight
Obesity
Intervention:
DRUG: Maridebart Cafraglutide
Maridebart cafraglutide will be administered SC.
Recruitment Status: RECRUITING
Sponsor: Amgen
Disclai...